Resumen

BARATA, Rui; CARDOSO, Filipa  y  PEREIRA, Tiago Assis. Hyperuricemia in Chronic Kidney Disease: a role yet to be explained. Port J Nephrol Hypert [online]. 2020, vol.34, n.1, pp.30-35. ISSN 0872-0169.  https://doi.org/10.32932/pjnh.2020.04.060.

The role of uric acid as an independent risk factor for chronic kidney disease development and progression is still a matter of discussion. Several observational studies showed a positive association between hyperuricemia and the progression of kidney dysfunction, but others did not, which probably derived from different biases and studies insufficiencies. Moreover, the results from studies on patients in hemodialysis and peritoneal dialysis are even more controversial, with some evidence pointing towards a protective role of uric acid in hemodialysis patients, but not in peritoneal dialysis. In addition to most evidence suggesting a role of uric acid in chronic kidney disease pathogenesis and progression, pharmacological treatment of asymptomatic hyperuricemia is still not indicated, with no consensus on either the uric acid level at which treatment would be beneficial, or the target-level to achieve. There are several studies on the renal benefits of xanthine oxidase inhibitors allopurinol and febuxostat, with heterogeneous results. Most of them showed a renoprotective effect of both drugs, delaying renal disease progression. However, the different results found in other studies makes it difficult to draw definitive conclusions. Despite recent evidence pointing toward an important role of uric acid in the pathogenesis and progression of kidney disorders, and the benefits of its treatment, there are still several unanswered questions, and well-conducted studies are needed to make valid conclusions.

Palabras clave : Chronic Kidney Disease; Disease prevention; Urate lowering therapy; Uric acid; Xanthine oxidase inhibitors.

        · texto en Inglés     · Inglés ( pdf )